54.09
-0.13(-0.24%)
Currency In USD
| Previous Close | 54.22 |
| Open | 53.8 |
| Day High | 55.56 |
| Day Low | 53 |
| 52-Week High | 91.83 |
| 52-Week Low | 26.7 |
| Volume | 636,876 |
| Average Volume | 360,327 |
| Market Cap | 1.1B |
| PE | -5.07 |
| EPS | -10.66 |
| Moving Average 50 Days | 46.77 |
| Moving Average 200 Days | 56.91 |
| Change | -0.13 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $129.71 as of August 03, 2025 at a share price of $54.09. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 3 years ago, it would be worth $1,119.88 as of August 03, 2025 at a share price of $54.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 29, 2025 12:00 PM GMT
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
GlobeNewswire Inc.
Jul 17, 2025 12:00 PM GMT
The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The EMBOLD cohort 2 pivotal trial is on track for topli
Praxis Precision Medicines to Participate in Upcoming Conferences
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders character